integrins

Advancing with cancer immunotherapeutics: CD29⁺ regulatory T cell antagonism
Francisco Javier Cubero, Pablo Sarobe, Gisa Tiegs

Gut Mar 2024, 73 (3) 391-392; DOI: 10.1136/gutjnl-2023-331048
Deciphering the vedolizumab dosing conundrum in IBD: when less is more
Timon Erik Adolph, Britta Siegmund

Gut Aug 2022, 71 (8) 1455-1456; DOI: 10.1136/gutjnl-2021-325893
Galectin-8 expression decreases in cancer compared with normal and dysplastic human colon tissue and acts significantly on human colon cancer cell migration as a suppressor
N Nagy, Y Bronckart, I Camby, H Legendre, H Lahm, H Kaltner, Y Hadari, P Van Ham, P Yeaton, J-C Pector, Y Zick, I Salmon, A Danguy, R Kiss, H-J Gabius

Gut Mar 2002, 50 (3) 392-401; DOI: 10.1136/gut.50.3.392
Blockade of the integrin αLβ2 but not of integrins α4 and/or β7 significantly prolongs intestinal allograft survival in mice
S Sarnacki, F Auber, C Crétolle, C Camby, M Cavazzana-Calvo, W Müller, N Wagner, N Brousse, Y Révillon, A Fischer, N Cerf-Bensussan

Gut Jul 2000, 47 (1) 97-104; DOI: 10.1136/gut.47.1.97
β6 integrinosis: a new lethal autosomal recessive ITGB6 disorder leading to impaired conformational transitions of the α_Vβ6 integrin receptor
Patrick Weil, Rhea van den Bruck, Thomas Ziegenhals, Stefan Juranek, Daniel Goedde, Valerie Orth, Stefan Wirth, Andreas C Jenke, Jan Postberg

Gut Jul 2020, 69 (7) 1359-1361; DOI: 10.1136/gutjnl-2019-319015
Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease
Sebastian Zeissig, Elisa Rosati, C Marie Dowds, Konrad Aden, Johannes Bethge, Berenice Schulte, Wei Hung Pan, Neha Mishra, Maaz Zuhayra, Marlies Marx, Maren Paulsen, Anne Strigli, Claudio Conrad, Dörthe Schuldt, Anupam Sinha, Henriette Ebsen, Sabin-Christin Kornell, Susanna Nikolaus, Alexander Arlt, Dieter Kabelitz, Mark Ellrichmann, Ulf Lützen, Philip C Rosenstiel, Andre Franke, Stefan Schreiber

Gut Jan 2019, 68 (1) 25-39; DOI: 10.1136/gutjnl-2018-316023
Mechanism of action of vedolizumab: do we really understand it?
Gerhard Rogler

Gut Jan 2019, 68 (1) 4-5; DOI: 10.1136/gutjnl-2018-316777
Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances
Sebastian Zundler, Emily Becker, Lisa Lou Schulze, Markus F Neurath

Gut Sep 2019, 68 (9) 1688-1700; DOI: 10.1136/gutjnl-2018-317977
Integrin a6 loss promotes colitis-associated colorectal cancer. Response to: “Integrin a6 variants and colorectal cancer” by Beaulieu JF
Adèle De Arcangelis, Mathias Chamaillard, Patricia Simon-Assmann, Michel Labouesse

Gut Dec 2018, 67 (12) 2227-2228; DOI: 10.1136/gutjnl-2017-315727
Integrin Î±6 variants and colorectal cancer
Jean-François Beaulieu

Gut Sep 2018, 67 (9) 1747-1748; DOI: 10.1136/gutjnl-2017-315415

Main menu

integrins

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

integrins

Pages